Rating Change
B. Riley Securities reiterated its Buy rating on MacroGenics, Inc. (NASDAQ:MGNX) on August 17, 2026.
reiterateNASDAQ:MGNX
B. Riley Securities Reiterates Buy Rating on MacroGenics, Inc. (MGNX)
B. Riley Securities reiterated its Buy rating on MacroGenics, Inc.
At publication ·
What changed
MacroGenics, Inc. (NASDAQ:MGNX) · reiterate
- Firm
- B. Riley Securities
- Rating
- Buy to Buy
- Price at event
- $4.06
- Market capitalization
- $89.5M
At a glance
Key takeaways
- B. Riley Securities reiterated a Buy rating on MacroGenics (MGNX) on August 17, 2026, with the stock trading at $4.06 and a market capitalization of $89.5 million.
Market Context
MacroGenics, Inc. operates in the Healthcare sector. The stock currently trades at $4.06 with a market capitalization of $89.5M. The stock has gained 150.6% over the past 52 weeks.
Analyst coverage from B. Riley Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for MacroGenics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for MacroGenics, Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 17, 2026 | B. Riley Securities | Buy | N/A |
| Apr 20, 2026 | Barclays | Overweight | N/A |
| Apr 10, 2026 | B. Riley Securities | Buy | N/A |
| Mar 10, 2026 | Barclays | Overweight | N/A |
| Nov 03, 2025 | HC Wainwright & Co. | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View MGNX Stock Page
Frequently Asked Questions
What does the Buy rating mean for MGNX?
A rating of Buy from B. Riley Securities reflects the analyst's outlook on MacroGenics, Inc. (NASDAQ:MGNX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MGNX forecast page.
